Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan.
Anticancer Res. 2011 Nov;31(11):3775-82.
The aim of this study was to investigate whether L-type amino acid transporter 1 (LAT1) expression can predict poor outcome after chemotherapy in patients with non-small cell lung cancer (NSCLC).
Immunohistochemistry was carried out to examine the expression of LAT1, CD98, vascular endothelial growth factor (VEGF), Ki-67, phosphorylation of Akt (p-Akt), phosphorylation of mammalian target of rapamycin (p-mTOR) and p53 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy.
Positive LAT1 and CD98 expression was recognized in 45% (25/56) and 34% (19/56), respectively. In NSCLC (N=56), LAT1, CD98, VEGF, Ki-67 and p53 were significant factors for predicting poor outcome, and adenocarcinoma was an independent factor for predicting favorable prognosis. LAT1 expression was closely associated with chemoresistance. In adenocarcinoma (N=37), a statistically significant inverse relationship was observed between the expression of LAT1, VEGF and Ki-67 and epidermal growth factor receptor (EGFR) mutation, and positive expression of LAT1 and VEGF was an independent factor for predicting poor prognosis after chemotherapy.
LAT1 expression may be useful for predicting response and outcome after systemic chemotherapy.
本研究旨在探讨 L 型氨基酸转运蛋白 1（LAT1）的表达能否预测非小细胞肺癌（NSCLC）患者化疗后的不良预后。
对 56 例接受铂类化疗的患者切除的肺肿瘤标本进行免疫组织化学分析，检测 LAT1、CD98、血管内皮生长因子（VEGF）、Ki-67、Akt 磷酸化（p-Akt）、哺乳动物雷帕霉素靶蛋白（mTOR）磷酸化（p-mTOR）和 p53 的表达。
分别有 45%（25/56）和 34%（19/56）的患者存在 LAT1 和 CD98 的阳性表达。在 NSCLC（N=56）中，LAT1、CD98、VEGF、Ki-67 和 p53 是预测不良预后的显著因素，腺癌是预测预后良好的独立因素。LAT1 表达与化疗耐药性密切相关。在腺癌（N=37）中，LAT1、VEGF 和 Ki-67 的表达与表皮生长因子受体（EGFR）突变呈显著负相关，LAT1 和 VEGF 的阳性表达是预测化疗后不良预后的独立因素。
LAT1 表达可能有助于预测全身化疗后的反应和预后。
